MaxCyte to Report Second Quarter 2024 Financial Results on
August 6, 2024
ROCKVILLE, MD, July
10, 2024 - MaxCyte, Inc., (NASDAQ: MXCT; LSE:
MXCT), a leading, cell-engineering focused
company providing enabling platform technologies to advance the
discovery, development and commercialization of next-generation
cell therapeutics and innovative bioprocessing applications,
announces that it will release financial results for the second
quarter 2024 after the U.S. market close on Tuesday, August 6th,
2024. Company management will host a conference call to discuss
financial results at 4:30 p.m. Eastern Time.
Earnings Conference
Call Details
Investors interested in listening to the conference
call are required to
register online. It is recommended to register at least a day
in advance. A live and archived webcast of the event will be
available on the "Events" section of the MaxCyte website at
https://investors.maxcyte.com/.
About
MaxCyte
At MaxCyte, we pursue cell engineering excellence to
maximize the potential of cells to improve patients' lives. We have
spent more than 20 years honing our expertise by building
best-in-class platforms, perfecting the art of the transfection
workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which
is based on our Flow Electroporation® technology, has
been designed to support the rapidly expanding cell therapy market
and can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx ™; a portfolio of
proprietary related processing assemblies or disposables; and
software protocols, all supported by a robust worldwide
intellectual property portfolio. By providing our partners with the
right technology, as well as scientific, technical and regulatory
support, we aim to guide them on their journey to transform human
health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and
LinkedIn.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler,
CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic
Collaborative
Valerie Enes
+1 408-497-8568
venes@spectrumscience.com
Nominated Adviser and Joint Corporate
Broker
Panmure Liberum
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886
2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
